Evidence suggests that BCR-ABL1 induced oncogenesis might require HCK, and HCK overexpression has been shown to be sufficient to induce imatinib resistance in CML. This evidence concerns the gene HCK and chronic myelogenous leukemia, BCR-ABL1 positive.